Dear Members,
Caught in the middle of the battle against COVID19, specially for countries like Italy or Spain, this newsletter wishes all the best to healthcare professionals, European citizens and to the whole ESC family in these hard times.
The WG on Cardiovascular Regenerative and Reparative Medicine celebrated its Second Scientific Retreat at the European Heart Agency (Brussels) on February 27-28th, just before the outbreak of the SARS-CoV-2 pandemic in Europe. During that meeting, WG members and key-opinion-leaders from Europe and the USA put the filed in perspective in 2020 by focusing on four main topics: new scenarios for reparative products like HFpEF and oncologic patients, pathobiological barriers for effective repair, the definitive role of myocardial fibrosis in cardiovascular failure, and the real potency of the human myocardium to heal itself by means of cardiac progenitors. On the other hand, the first Current Opinion paper of the WG, which emanates from the First Scientific Retreat and which summarizes the field in terms of products, animal studies and clinical trials, is currently under review in one of the ESC Family Journals.
At the same time, the WG executive team is planning future educational activities (ie, ESC webinars) and the number of members is steadily growing (167 members so far). We encourage all basic and clinical scientists with interest in this field to become member here following the ESC WGs instructions.
Importantly, the WG is electing new Ordinary Nucleus Members 2020-2022 (5 positions), deadline to vote is 30 June 2020. Visit this page for more information about the elections.
Our mission: To reduce the burden of cardiovascular disease.